Oryx Translational Medicine

Oryx Translational Medicine is a private, Munich-based biotech company founded in 2018 with a distinctive 'academic-to-pharma' bridge model. It specializes in advancing early-stage academic oncology discoveries, particularly in RNA/gene therapy, vaccines, and viral technology, through to clinical proof-of-concept. The company has a lean operational structure, leveraging in-house expertise and outsourced execution to build a capital-efficient pipeline, with three programs that have already demonstrated safety and early efficacy signals in clinical trials. Its strategy is to de-risk innovative therapies for subsequent partnership with larger pharmaceutical companies.

Translational medicine model specializing in advancing academic oncology research (RNA/gene therapy, vaccines, viral tech) to clinical proof-of-concept.

Oryx competes in the oncolytic virotherapy and immuno-oncology space with companies like Amgen (Imlygic), DNAtrix, and others, as well as with numerous biotechs and academic spin-outs also seeking to partner assets at the clinical proof-of-concept stage. Its differentiation lies in its focused translational expertise and lean model for advancing academic science.